Cristina Chimenti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/456667/publications.pdf

Version: 2024-02-01

28 papers 1,819 citations

567281 15 h-index 27 g-index

28 all docs

 $\begin{array}{c} 28 \\ \text{docs citations} \end{array}$

times ranked

28

2043 citing authors

#	Article	IF	CITATIONS
1	Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. European Heart Journal, 2009, 30, 1995-2002.	2.2	461
2	Immunosuppressive Therapy for Active Lymphocytic Myocarditis. Circulation, 2003, 107, 857-863.	1.6	434
3	CMR Sensitivity Varies With Clinical Presentation and Extent of Cell Necrosis in Biopsy-Proven Acute Myocarditis. JACC: Cardiovascular Imaging, 2014, 7, 254-263.	5.3	177
4	Contribution and Risks of Left Ventricular Endomyocardial Biopsy in Patients With Cardiomyopathies. Circulation, 2013, 128, 1531-1541.	1.6	168
5	Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. International Journal of Molecular Sciences, 2020, 21, 8118.	4.1	148
6	Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. International Journal of Molecular Sciences, 2018, 19, 3726.	4.1	63
7	Clozapine-Induced Hypersensitivity Myocarditis. Chest, 2004, 126, 1703-1705.	0.8	53
8	Necrotizing Myocardial Vasculitis in Churg-Strauss Syndrome. Chest, 1998, 114, 1484-1489.	0.8	39
9	Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 419-429.	2.1	33
10	Myocardial expression of Tollâ€like receptor 4 predicts the response to immunosuppressive therapy in patients with virusâ€negative chronic inflammatory cardiomyopathy. European Journal of Heart Failure, 2017, 19, 915-925.	7.1	30
11	Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. European Heart Journal, 2022, 43, 3463-3473.	2.2	28
12	Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease. Journal of Thrombosis and Thrombolysis, 2021, 51, 571-576.	2.1	23
13	Potential Role of eNOS Genetic Variants in Ischemic Heart Disease Susceptibility and Clinical Presentation. Journal of Cardiovascular Development and Disease, 2021, 8, 116.	1.6	18
14	Cushing Syndrome Cardiomyopathy. Circulation: Cardiovascular Imaging, 2016, 9, e004569.	2.6	17
15	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. International Journal of Molecular Sciences, 2021, 22, 7650.	4.1	17
16	Prevalence and Clinical Implications of COVID-19 Myocarditis. Cardiac Electrophysiology Clinics, 2022, 14, 53-62.	1.7	16
17	A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy. ESC Heart Failure, 2022, 9, 241-250.	3.1	16
18	Microvascular Angina as Prehypertrophic Presentation of Fabry Disease Cardiomyopathy. Circulation, 2014, 130, 1530-1531.	1.6	15

#	Article	IF	CITATIONS
19	Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization. International Journal of Cardiology, 2019, 292, 141-147.	1.7	14
20	Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Failure Reviews, 2023, 28, 709-721.	3.9	14
21	The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts. Orphanet Journal of Rare Diseases, 2020, 15, 86.	2.7	9
22	Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome. European Heart Journal, 2021, 42, 1609-1617.	2.2	8
23	Fatal myocardial co-infection by Toxoplasma gondii and Parvovirus B19 in an HIV patient. Aids, 2007, 21, 1386-1388.	2.2	6
24	Hypersensitivity Myocarditis and Necrotizing Coronary Vasculitis by Clomipramine Causing Steroid-Sensitive Cardiogenic Shock. Circulation: Cardiovascular Imaging, 2019, 12, e008736.	2.6	5
25	Early myocardial gadolinium enhancement in patients with myocarditis: Validation of "Lake Louise consensus―criteria using a single bolus of 0.1 mmol/Kg of a high relaxivity gadolinium-based contrast agent. European Journal of Radiology, 2017, 95, 89-95.	2.6	4
26	Kappa-light Chain Amyloid Overlapping Hypertrophic Cardiomyopathy With Myocardial Noncompaction. Circulation: Cardiovascular Imaging, 2020, 13, e010379.	2.6	2
27	Response to Letter Regarding Article, "Contribution and Risk of Left Ventricular Endomyocardial Biopsy in Patients With Cardiomyopathies: A Retrospective Study Over a 28-Year Period― Circulation, 2014, 130, e31.	1.6	1
28	239â€fRole of eNOS genetic variants on ischaemic heart disease susceptibility and acute coronary syndrome presentation. European Heart Journal Supplements, 2021, 23, .	0.1	O